Latest Conference Articles

Circulating tumor cells have previously been reported to be prognostic in other solid tumors: can they become a prognostic biomarker in cervical cancer?

A triage algorithm may identify patients with presumed advanced ovarian cancer who represent preoperatively defined candidates for diagnostic laparoscopy.

Barbara Ann Goff, MD, discusses an analysis looking at the care of ovarian cancer.

Two newly reported studies are providing more insight into the efficacy and safety profile of the PARP inhibitor olaparib in ovarian cancer.

Bradley J. Monk, MD, FACOG, FACS, on bevacizumab in combination with the vascular disrupting agent fosbretabulin for the treatment of patients with recurrent ovarian, tubal, or peritoneal carcinoma.

The addition of bevacizumab to a doublet chemotherapy regimen extended OS by nearly 5 months compared with standard chemotherapy alone in women with platinum-sensitive recurrent ovarian cancers.

A 2:1 open-label phase II trial of the FANG vaccine achieved a marked delay in time to progression, in all 14 of 21 patients with stage III/IV ovarian cancer who participated. The other 7 patients did not receive the vaccine.

Robert L. Coleman, MD, FACOG, FACS, professor, The University of Texas MD Anderson Cancer Center, discusses the results and key takeaways from GOG0213.

Although treatments and cure rates have increased significantly over the past 60 years for patients with HL, it is crucial that practitioners stay up-to-date on research that can affect outcomes for their patients with this uncommon form of cancer.

Androgen deprivation therapy (ADT) with or without chemotherapy led to similar survival in men with advanced, metastatic hormone-sensitive prostate cancer, according to an updated analysis of a randomized trial.

Scott T. Tagawa, MD, MS, associate professor, Clinical Medicine and Urology, Weill Cornell Medical College, discusses PSMA-targeting agents for the treatment of prostate cancer.

The FDA’s recent approval of the first PARP inhibitor, coupled with current research, suggests that this new class of targeted therapy has great potential to help not only patients with ovarian cancer for whom the agent is indicated but also individuals with breast cancer.

The treatment options for patients with relapsed/refractory multiple myeloma are expanding rapidly, notably through clinical trial evidence supporting a number of three-drug combination regimens.

Heterogeneity, which can result in treatment resistance, is commonly underestimated and misunderstood, representing an important area of future research.

An immune checkpoint inhibitor combined with active immunotherapy has a potential positive effect on overall survival (OS) in the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Jennifer H. Kuo, MD, director, Thyroid Biopsy Program, Columbia University, discusses a study looking at the incidence of thyroid cancer among breast cancer survivors.

While not appropriate for all patients with ER-positive breast cancer, neoadjuvant endocrine therapy could play an important role in select groups of women with comorbidities or those with ER-rich/luminal A disease.

Cytogenetic and molecular data are becoming increasingly important in the individualization of treatment of patients with acute myeloid leukemia (AML).

Tumor genome profiling identifies driver mutations in breast tumors, however, it is still too early to use this information in clinical decision making, according to Hope S. Rugo, MD.

The antiangiogenic agent pazopanib combined with paclitaxel showed significant antitumor activity in a phase II study of patients with relapsed/refractory urothelial cancer.

Lori J. Wirth, MD, discusses an open-label extension of the phase III SELECT trial, which looked at lenvatinib versus placebo for differentiated thyroid cancer.

Poly (ADP-ribose) polymerase-1 (PARP-1) is a multifunctional, chromatin-regulating protein. PARP inhibitors are currently undergoing clinical trials as potential targeted therapies for the treatment of breast, uterine, colorectal, and ovarian cancer.

The oral androgen receptor inhibitor, enzalutamide, blocks several steps in the androgen receptor signaling pathway and prevents the entry of androgen receptor into the cell nucleus.

A recent study showed that the androgen receptor (AR) splice variant AR-V7 activated full-length AR through an alternative biosynthesis pathway and increased citrate utilization through altered metabolic activities, which may partially explain its resistance to conventional androgen deprivation therapy (ADT).

Steven I. Sherman, MD, discusses the relationship between thyroid-stimulating hormone levels and outcomes from the phase III SELECT trial.

On February 13, 2015, the FDA approved lenvatinib for treatment of locally recurrent or metastatic differentiated thyroid cancer that is refractory to radioactive iodine therapy.

Frances Carr, PhD, professor, Department of Pharmacology, The University of Vermont, discusses the relationship between the thyroid hormone receptor and Runx2 expression in thyroid cancer cells.

According to a recent descriptive analysis of the VA Corporate Data Warehouse, veterans who reported Agent Orange exposure had higher rates of thyroid cancer compared to the overall national VA health care patient population.

The incidence of thyroid cancer, which is now the most rapidly increasing endocrine malignancy, has been increasing at a rate of 3% to 5% per year, resulting in a near doubling in the past 30 years.

In an analysis of adverse events following treatment of patients with advanced melanoma with ipilimumab and nivolumab, combination therapy was associated with a 22% incidence of either thyroiditis or hypothyroidism and a 9% incidence of hypophysitis.